Spoken Alpha
CAPR
CAPRICOR THERAPEUTICS, INC.
Overview
CAPRICOR THERAPEUTICS, INC is a Healthcare company operating in Biotechnology with a $1.64B market cap.
CAPR missed consensus EPS by 0.2% in Q1 FY2026, reported May 19, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1220 Q&A exchanges
- Q4 FY2025Earnings2026-03-1217 Q&A exchanges
- Q3 FY2025Earnings2025-11-1028 Q&A exchanges
- Q2 FY2025Earnings2025-08-1826 Q&A exchanges
- Q1 FY2025Earnings2025-05-1321 Q&A exchanges
- Q4 FY2024Earnings2025-03-1921 Q&A exchanges
- Q3 FY2024Earnings2024-11-1313 Q&A exchanges
- Q2 FY2024Earnings2024-08-0814 Q&A exchanges
- Q1 FY2024Earnings2024-05-1310 Q&A exchanges
- Q4 FY2023Earnings2024-02-2914 Q&A exchanges
- Q3 FY2023Earnings2023-11-149 Q&A exchanges
- Q2 FY2023Earnings2023-08-077 Q&A exchanges
- Q1 FY2023Earnings2023-05-1111 Q&A exchanges
- Q4 FY2022Earnings2023-03-1515 Q&A exchanges
- Q3 FY2022Earnings2022-11-1014 Q&A exchanges
- Q2 FY2022Earnings2022-08-1011 Q&A exchanges
- Q1 FY2022Earnings2022-05-104 Q&A exchanges
- Q4 FY2021Earnings2022-03-105 Q&A exchanges
- Q3 FY2021Earnings2021-11-095 Q&A exchanges
- Q2 FY2021Earnings2021-08-1224 Q&A exchanges
- Q1 FY2021Earnings2021-05-1323 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-19EPS$-0.59 vs $-0.48-23.4%Rev$0 vs ——EODHD
- Q4 FY20252026-03-24EPS$-0.62 vs $-0.51-20.9%Rev$0 vs ——EODHD
- Q3 FY20252025-11-09EPS$-0.54 vs $-0.540.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.57 vs $-0.48-18.8%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.53 vs $-0.32-66.7%Rev$0 vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.16 vs $-0.09-70.2%Rev$11.1M vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.38 vs $-0.36-5.6%Rev$2.3M vs ——EODHD
- Q2 FY20242024-08-06EPS$-0.35 vs $-0.36+2.8%Rev$4.0M vs ——EODHD
- Q1 FY20242024-05-12EPS$-0.31 vs $-0.11-100.0%Rev$4.9M vs ——EODHD
- Q4 FY20232024-02-28EPS$-0.02 vs $-0.09+77.8%Rev$12.1M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.25 vs $-0.29+13.8%Rev$6.2M vs ——EODHD
- Q2 FY20232023-08-06EPS$-0.29 vs $-0.35+17.1%Rev$3.9M vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.31 vs $-0.32+3.1%Rev$3.0M vs ——EODHD
- Q4 FY20222023-03-14EPS$-0.31 vs $-0.33+6.1%Rev$959.9K vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.26 vs $-0.29+10.3%Rev$1.6M vs ——EODHD
- Q2 FY20222022-08-09EPS$-0.29 vs $-0.25-16.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.32 vs $-0.320.0%Rev$0 vs ——EODHD
- Q4 FY20212022-03-09EPS$-0.26 vs $-0.19-36.8%Rev$244.7M vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.17 vs $-0.22+22.7%Rev$0 vs ——EODHD
- Q2 FY20212021-08-11EPS$-0.21 vs $-0.23+8.7%Rev$204.1K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-19 | $-0.59 | $-0.48 | -23.4% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-24 | $-0.62 | $-0.51 | -20.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-0.54 | $-0.54 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.57 | $-0.48 | -18.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.53 | $-0.32 | -66.7% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.16 | $-0.09 | -70.2% | $11.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.38 | $-0.36 | -5.6% | $2.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.35 | $-0.36 | +2.8% | $4.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.31 | $-0.11 | -100.0% | $4.9M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.02 | $-0.09 | +77.8% | $12.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.25 | $-0.29 | +13.8% | $6.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.29 | $-0.35 | +17.1% | $3.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.31 | $-0.32 | +3.1% | $3.0M | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $-0.31 | $-0.33 | +6.1% | $959.9K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.26 | $-0.29 | +10.3% | $1.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.29 | $-0.25 | -16.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.32 | $-0.32 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.26 | $-0.19 | -36.8% | $244.7M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.17 | $-0.22 | +22.7% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-11 | $-0.21 | $-0.23 | +8.7% | $204.1K | — | — | EODHD |
Source: EODHD. CAPR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks CAPR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.90 | $2.69 | +7.8% | -7.9% | -6.5% |
| Q4 FY2026 | $2.95 | $2.59 | +14.0% | +1.6% | +2.6% |
| Q3 FY2026 | $3.05 | $2.67 | +14.1% | +1.0% | -0.1% |
| Q2 FY2026 | $3.09 | $2.56 | +20.6% | -2.0% | -0.8% |
| Q1 FY2025 | $3.10 | $2.54 | +21.9% | -8.3% | -5.8% |
| Q4 FY2025 | $2.99 | $2.73 | +9.4% | -2.3% | -5.1% |
| Q3 FY2025 | $2.84 | $2.55 | +11.2% | -5.5% | -5.1% |
| Q2 FY2025 | $3.34 | $2.77 | +20.6% | -1.9% | -0.3% |
| Q1 FY2024 | $3.22 | $2.87 | +12.2% | +1.0% | -0.5% |
| Q4 FY2024 | $3.12 | $2.81 | +11.0% | +0.9% | +3.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Linda MarbanCEO1 yr 5 mo21 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Anthony BergmannCFO1 yr 5 mo7 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q1 FY2026
- Karen KrasneyEVP, GENERAL COUNSEL1 yr 6 mono recorded callsCurrentSample
DIVISION_HEAD since 2024 • 5/8 beats (63%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CAPR.
$ curl https://api.spokenalpha.com/v1/companies/CAPRFAQ
Frequently asked about CAPR
Where can I find CAPRICOR THERAPEUTICS, INC.'s (CAPR) earnings call transcripts?
Spoken Alpha indexes CAPR's earnings call transcripts at https://spokenalpha.com/companies/CAPR. Each call links to attributed speakers and parsed analyst Q&A. CAPRICOR THERAPEUTICS, INC.'s own investor relations page is at https://www.capricor.com/investors.
When was CAPRICOR THERAPEUTICS, INC.'s most recent earnings call?
CAPRICOR THERAPEUTICS, INC. (CAPR) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
What sector is CAPR in?
CAPRICOR THERAPEUTICS, INC. (CAPR) operates in the Healthcare sector (Biotechnology industry).